Role of graft-versus-host disease in the development of secondary skin cancers in hematopoietic stem cell transplant recipients: A meta-analysis
To the Editor: Hematopoietic stem cell transplant (HSCT) recipients are at increased risk for developing secondary skin cancers. 1, 2 Acute and chronic graftversus-host disease (GVHD) are considered potential risk factors; however, their effect has not been fully assessed. To further evaluate the impact of GVHD on secondary skin cancer development, a meta-analysis was performed by using random effects models comparing incidence of secondary skin cancers in HSCT recipients on the basis of GVHD status.
An electronic search in PubMed and Cochrane was conducted using key words ''graft versus host,'' ''GVHD,'' ''graft vs host,'' ''stem cell transplant,'' ''bone marrow transplant,'' ''hematopoietic stem cell transplant,'' ''HSCT,'' and ''allogeneic.'' Each were individually searched with ''AND'' followed by ''skin malignancy,'' ''skin cancer,'' ''melanoma,'' ''squamous cell,'' or ''basal cell.'' Included studies analyzed skin cancer as a primary outcome of all HSCTs performed, and provided information on skin cancers and GVHD status. By using PRISMA ( preferred reporting items for systematic reviews and meta-analyses) guidelines, 1952 records were screened, 541 duplicates were removed, and 1411 original studies were reviewed for study eligibility. Meta-analysis was performed by using Review Manager 5.3 statistical software. Study heterogeneity was assessed using I 2 tests. The random effects model was chosen to calculate summary statistics to allow for variability among patient populations and procedures across all studies. Overall effect sizes were determined by relative risk (RR) with the 95% confidence interval (CI). A P value \.05 was considered statistically significant. Study quality was assessed using Downs and Black instrument. Six retrospective studies and 1 prospective study met inclusion criteria, and yielded a total of 50,951 HSCT patients, among whom 166 skin cancers developed after transplant (Supplemental Table I ; available at http://www.jaad.org). Acute GVHD was not associated with increased risk for basal cell carcinoma (BCC) (P ¼ .88), squamous cell carcinoma (SCC) (P ¼ .90), or melanoma (P ¼.28) (Supplemental Fig 1, A-C; available at http://www.jaad.org). Study heterogeneity (I 2 ) for acute GVHD with BCC, SCC, or melanoma was low (0%, 0%, and 19%, respectively). Chronic GVHD was associated with increased incidence of BCC (RR 1.95, 95% CI 1.29-2.95; P ¼ .002) and SCC (RR 5.31, 95% CI 2.39-11.81; P \ .001) but had no effect on malignant melanoma (P ¼ .1) (Fig 1, A and B; Supplemental Fig 2; available at http://www.jaad.org). Heterogeneity of studies for chronic GVHD with SCC, BCC, or melanoma was low (0%, 0%, and 43%, respectively).
The heightened incidence of SCC and BCC in chronic GVHD patients indicates a need for rigorous, long-term dermatologic surveillance of this high-risk population. Studies have shown that secondary skin cancers occur at specific sites in cutaneous chronic GVHD, suggesting that chronic inflammation imposed by GVHD lends itself to increased cell division and acquisition of mutations, resulting in subsequent formation of cutaneous neoplasms. 3, 4 Limitations of our data include that our results were based on unadjusted estimates. Controlling for confounders such as age, sex, race, and type of immunosuppressive regimen might yield more reliable results. In addition, the number of skin cancers in our HSCT population was not reflective of total number of skin cancers before transplant. Continued evaluation of large cohort studies with long-term follow-up are needed to assess the relative risk for secondary skin cancers and various other neoplasms among those with GVHD. Black dots in palmoplantar warts-challenging a concept: A histopathologic study To the Editor: Palmoplantar warts are diagnosed by dermatologists on a daily basis. Clinically, many lesions have characteristic small black dots that are considered to represent thrombi in dermal vessels. 1 This concept has been taught by dermatologists over many decades and is found in the newest versions of our standard literature. 2, 3 However, to our knowledge, this concept has not been sufficiently substantiated by morphologic studies. A few publications have described thrombi in association with an infarctive process showing black dots with rapid progression to blackening and regression of the wart clinically, but this is observed in less than 5% of warts. 4 We therefore histologically investigated formalin-fixed, paraffin-embedded specimens of 18 completely excised palmoplantar warts in narrow step sections for the presence of dermal microthrombi, and in a second step, we examined curettage material of 2 additional plantar warts that had black dots clinically. The study was approved by the Ethical Committee of Kanton Zurich, Switzerland (Business Administration System for Ethics Committees Identifier 2015-00227). None of the 18 warts (0%) showed thrombi in dermal vessels when hematoxylin-eosin (HE) stain was used Risk ratios and 95% CIs for association between aGVHD and incidence of secondary skin cancers: basal cell carcinoma (A), squamous cell carcinoma (B), and malignant melanoma (C). aGVHD, Acute graft-versus-host disease; CI, confidence interval; GVHD, graft-versus-host disease.
Supplemental Fig 2.
Risk ratios and 95% CIs for association between cGVHD and incidence of malignant melanoma. cGVHD, Chronic graft-versus-host disease; CI, confidence interval; GVHD, graft-versus-host disease. 
